Biotronik announces the sole 42 joule implantable cardioverter defibrillator (ICD) in the US

 

Orange County, CA - November 11th 2016 - Biomedical company Biotronik recently announced the launch of Inventra HF-T, an implantable cardioverter defibrillator (ICD) that can deliver a more powerful jolt at a faster rate. ICDs are for patients with tachycardia, or fast arrhythmias, which require a controlled burst of impulses or shocks to the heart to convert dangerous arrhythmias back to a normal rhythm. The quicker a shock is delivered, the greater the likelihood of patient survival.

Most current ICDs on the market produce around 36 joules of energy, the industry standard, but patients with larger hearts and those with a reduced ejection fraction, where the heart muscle does not contract effectively and less oxygen-rich blood is sent out to the body, often need a more substantial shock to regain a stable arrhythmia. The Inventra ICD is able to deliver 42 joules efficaciously to the heart on the first shock, the only of its kind available in the United States.

For an increasing number of patients – specifically those with larger cardiac anatomy and lower ejection fraction – a shock higher than 36-37 J may be needed to convert irregular arrhythmia,” said Dr. Mark Mascarenhas, electrophysiologist at Jersey Shore University Medical Center in Neptune, New Jersey, in a press release from Biotronik. “For such patients, a CRT-D is able to heighten the chance of reversing the irregular arrhythmia. With the Inventra HF-T’s availability, patients with heart failure will be able to receive this life-saving therapy.”

 Biotronik announces the sole 42 joule implantable cardioverter defibrillator (ICD) in the US

The device features Biotronik Home Monitoring, allowing wireless patient monitoring and Home Monitoring-supported follow-ups with remote scheduling. The Heart Failure Monitor maintains continuous monitoring of clinical parameters for the earliest detection of changes in patients’ heart condition, leading to a more than 50% reduction in mortality for heart failure patients. This has been proven in clinical trials to reduce the number of patients who receive inappropriate shocks by 52%.

The device’s DF4 connector simplifies implantation, reducing the time necessary for the procedure and the ICDs have a lifespan of up to 7 and half years, depending on frequency of use.

"We invest significantly in research and development focused on advancements that improve patient lives and reduce risks, for the patient and the provider,” said Marlou Janssen, President, BIOTRONIK, Inc. in a press release from Biotronik. “I am proud that for the first time, heart failure ICD patients in the US can receive ultra-high energy therapy when needed."

Contact Ampronix:

Increasing Breastfeeding Rates

Email: info@ampronix.com 

International Sales: +1 949-273-8000

Domestic Sales: 1800-400-7972 for US and Canada

Follow Us:

FacebookTwitterLinkedIn

Share This Article:

TwitterFacebookLinkedIn

View our Product Catalog Online Here

 

About Ampronix

Ampronix is a renowned authorized master distributor of the medical industry's top brands as well as a world-class manufacturer of innovative technology. Since 1982, Ampronix has been dedicated to meeting the growing needs of the medical community with its extensive product knowledge, outstanding service, and state-of-the-art repair facility. Ampronix prides itself on its ability to offer tailored, one-stop solutions at a faster and more cost-effective rate than other manufacturers. Ampronix is an ISO & ANSI/ESD certified facility. To learn more go here.

 Biotronik announces the sole 42 joule implantable cardioverter defibrillator (ICD) in the US   Orange County, CA – November 11th 2016 – Biomedical company Biotronik recently announced the launch of Inventra HF-T, an implantable cardioverter defibrillator (ICD) that can deliver a more powerful jolt at a faster rate. ICDs are for patients with tachycardia, or fast arrhythmias, […]